THERAPY DOSSIER · th-127d235a4519

Exosomes from bone marrow derived endothelial progenitor cells transfected with miR-126 mimics, compared with exosomes from scrambler-transfected cells

Biologic · EPC-derived exosomes engineered with miR-126 mimic; extracellular-vesicle gene construct.

Evidence & regulatory context

Mechanism: EPC-derived exosomes engineered with miR-126 mimic; extracellular-vesicle gene construct.
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 33009888 ↗2020Reported benefit

Exosomes from miRNA-126-modified endothelial progenitor cells alleviate brain injury and promote functional recovery after stroke.

MouseIschaemia-reperfusionCerebral (MCAO/stroke)db/db type 2 diabetic recipients; db/c donors for endothelial progenitor cellsn = 143 db/db mice underwent occlusion, 11 died, 132 used; n =…Intravenous, tail veinApproximately 50 microgram total exosome protein per mouse…2 hours after middle cerebral artery occlusion

Model: Middle cerebral artery occlusion induced ischaemic stroke in db/db type 2 diabetic mice

miR-126 mimic transfection raised miR-126 about 4-fold in cells and 6-fold in exosomes without altering exosome size. Injected exosomes co-localised with endothelial cells, neurons, astrocytes and microglia in the peri-infarct area. Exosomes reduced infarct volume on days 2 and 14, with miR-126 enr…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…